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Summary  
Background 
Inherited thrombocytopenias (IT) are heterogeneous genetic disorders which frequently 
represent a diagnostic challenge. Requirement of highly specialized tests for diagnosis 
represents a particular problem in resource-limited settings. To overcome this difficulty, 
we applied a diagnostic algorithm and developed a collaboration program with a 
specialized international center in order to increase the diagnostic yield in a cohort of 
patients in Argentina. 
Methods 
Based on the algorithm, initial evaluation included collection of clinical data, platelet 
size, blood smear examination and platelet aggregation tests. Confirmatory tests were 
performed according to diagnostic suspicion, and included platelet glycoprotein 
expression, immunofluorescence for myosin-9 in granulocytes and platelet 
thrombospondin-1 and molecular screening of candidate genes.  
Results 
Thirty-one patients from 14 pedigrees were included, age was 32 (4-72) years, platelet 
count was 72 (4-147) x109/L. Autosomal dominant inheritance was found in 9 (64%) 
pedigrees, 10 (71%) had large platelets and 9 (29%) patients presented with syndromic 
forms. A definitive diagnosis was made in 10 of 14 pedigrees and comprised MYH9-
related disease in 4, while classic and monoallelic Bernard-Soulier syndrome, gray 
platelet syndrome, X-linked thrombocytopenia, Thrombocytopenia 2 (ANKRD26 
mutation) and familial platelet disorder with predisposition to acute myelogenous 
leukemia were diagnosed in 1 pedigree each.  
Conclusions 
Adoption of an established diagnostic algorithm and collaboration with an expert 
referral center proved useful for diagnosis of IT patients in the setting of a developing 
country. This initiative may serve as a model to develop international networks with the 
goal of improving diagnosis and care of patients with these rare diseases.  
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Inherited thrombocytopenias (IT) are relatively rare and underdiagnosed genetic 
disorders. They comprise heterogeneous medical conditions which range from severe 
diseases which present since birth with profuse bleeding to others in which patients are 
asymptomatic and thrombocytopenia is identified during routine laboratory 
examination. Recognition of these disorders is essential to avoid misdiagnosis as 
immune thrombocytopenia, which leads to useless and potentially harmful therapy, 
such as corticosteroids or splenectomy. Significant advances have been made in 
recent years regarding the molecular etiology of IT. Most of the identified genetic 
defects involve key regulators of megakaryopoiesis and thrombopoiesis that lead to 
defects in platelet production, although in certain disorders shortened platelet life-span 
represents an additional mechanism underlying thrombocytopenia [1]. Newly identified 
mutations in ANKRD26 in patients with Thrombocytopenia 2 (THC2) has contributed to 
diagnosis of patients with IT harbouring normal-sized platelets [2], while efforts to 
discover the genetic defect underlying Gray Platelet Syndrome (GPS) have led to the 
recent finding of mutations in NBEAL2 [3-5]. Appropriate characterization of IT is 
important for patient diagnosis, prognosis and genetic counselling and may help guide 
treatment decisions, especially regarding the use of Thrombopoietin-mimetics, which 
have been recently shown to improve platelet counts and reduce bleeding in patients 
with MYH9-related disease (MYH9-RD) [6].  
However, IT frequently represent a diagnostic challenge, even after extensive 
diagnostic work-up. This is due to the requirement of specialized laboratory and 
molecular tests and to the fact that the disease-causing mutation remains in many 
cases still unknown. To guide the diagnostic approach, an algorithm was proposed by 
the Italian Gruppo di Studio delle Piastrine. This is based on assessment of platelet 
size and the presence or absence of additional clinical features associated with 
thrombocytopenia, followed by simple laboratory screening tests and, finally, according 
to diagnostic suspicion, by more complex studies for diagnostic confirmation [7]. 
Requirement of highly specialized tests represents a particular problem in resource-
limited countries, in which stepwise use of available resources is critical for adequate 
classification and accurate diagnosis of patients. To circumvent this problem, we 
applied the aforementioned diagnostic algorithm, optimized the use of local resources 
and developed a collaborative initiative with a specialized center in Italy with the goal of 
increasing the diagnostic yield in a cohort of patients with IT in Argentina. Using this 
approach, a definitive diagnosis could be established in 10 (71.4%) of 14 IT pedigrees 
included in this study, demonstrating the feasibility of this strategy to maximize 
resources and improve diagnosis and care of IT patients in this setting. 
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Patients and Methods 
 
Patients 
Patients with platelet counts below 150 x 109/L and a history of thrombocytopenia in 
first- or second-degree relatives and/or features suggestive of IT, such as 
sensorineural hearing loss, nephropathy, Döhle-like bodies, congenital malformations, 
family history positive for myeloid neoplasms and immunodeficiency, who were 
followed at the Instituto de Investigaciones Médicas Alfredo Lanari from 2001 to 2011, 
were recruited in a consecutive manner. In addition, after exclusion of non-genetic 
causes of thrombocytopenia, patients with giant platelets, microthrombocytes or those 
with thrombocytopenia refractory to ITP treatment in whom platelet kinetic studies 
showed normal platelet life-span, were also considered eligible for this study. Our 
institution is a referral center for patients with platelet disorders, primarily involved in 
the care of adult patients, while children are referred for diagnostic evaluation from 
affiliated pediatric institutions. The study was approved by the local Ethics Committee 
and patients or their legal guardians signed an informed consent. Diagnostic work-up 
was carried out following an algorithm proposed by the Italian Gruppo di Studio delle 
Piastrine [7], which is based on two diagnostic phases with increasing levels of 
complexity. Initial evaluation includes platelet size and the presence or absence of 
clinical features other than thrombocytopenia, according to which patients are classified 
as presenting with syndromic or non-syndromic forms, and categorized based on the 
presence of large, normal-sized or small platelets. Platelet function tests and blood 
smear examination are performed at this stage and may further guide subsequent 
approach. According to initial suspicion, specialized tests are performed, including flow 
cytometry, analysis of myosin-9 distribution and molecular studies. A government-
supported collaboration program for diagnosis of IT was developed between centers in 
Argentina and Italy. Studies unavailable at the local institution were performed at the 
referral center in the setting of this collaboration, the aims of which were, in addition, to 
train health professionals and to help build local capacities.  
 
Platelet count and size and blood smear examination 
Platelet count was determined by microscopy, while automated platelet count and 
mean platelet volume (MPV) were assessed in an impedance-based electronic cell 
counter (Coulter, FL). Mean platelet diameter (MPD) was determined by measuring the 
largest diameter of 100 platelets in May-Grünwald-Giemsa-stained blood smears by 
using the VideoTesT-Master image analysis software (St. Petersburg, USSR). Smears 
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were examined for the presence of Döhle-like bodies and cell morphology was 
recorded.  
 
Platelet aggregation tests 
Platelet-rich plasma (PRP) was prepared by centrifugation or, in patients with large 
platelets, by allowing the sample to sediment. Aggregation in response to adenosine 
diphosphate (ADP), 2μM; epinephrine, 1μM; collagen, 4μg/ml, arachidonic acid, 1mM 
(Biopool, Bray, Ireland) was evaluated in a lumiaggregometer (Chrono-Log Corp, PA, 
USA) and compared to a control sample adjusted to the same platelet count. In 
addition, spontaneous platelet aggregation (SPA) and ristocetin-induced platelet 
aggregation (RIPA) with 1.5 mg/mL and 0.5 mg/mL (low-dose) ristocetin (Biopool) was 
assessed.  
 
Flow cytometry analysis for platelet glycoproteins  
Platelet surface glycoprotein (GP) expression was analyzed in a flow cytometer after 
incubation of PRP with fluorescein isothiocyanate (FITC)- or phycoerythrin-conjugated 
monoclonal antibodies to GPIIIa (CD61), GPIbα (CD42b) and GPIX (CD42a) (BD 
Biosciences, San José, CA, USA). Both the percentage of positive platelets and the 
ratio between mean fluorescence intensity (MFI) for the patient and the control were 
calculated.  
 
Myosin-9 distribution pattern by immunofluorescence 
Analysis of myosin-9 distribution on granulocytes was performed on blood smears after 
staining with mouse NMG2 monoclonal antibody followed by detection with Alexa Fluor 
488-conjugated goat anti-mouse secondary antibody and analyzed on a fluorescence 
microscope, as described [8]. 
 
Immunofluorescence analysis for thrombospondin-1 
Platelet thrombospondin-1 (TSP1) content was assessed on blood smears by 
immunostaining with a mouse anti-Thrombospondin-1 antibody (Sigma Aldrich, St. 
Louis, MO, USA) followed by a FITC or Alexa Fluor 594-conjugated goat anti-mouse 
secondary antibody. Platelets were identified by F-actin labeling with tetramethyl 
rhodamine isothiocyanate (TRITC)- or Alexa Fluor 488-conjugated Phalloidin and 
examined under a fluorescence microscope. For analysis, platelets were classified 
according to the number of TSP1-positive granules into platelets displaying >5 
granules and those with <5 granules, as reported [9]. 
 
A
cc
ep
te
d 
A
rt
ic
le
 
© 2012 International Society on Thrombosis and Haemostasis 
Mutation analysis 
For mutation testing, sequencing of all exons and exon/intron splice junctions of 
GP1BA, NBEAL2 and RUNX1 and of the 5’-untranslated region (5’-UTR) of ANKRD26 
was performed. For MYH9 analysis, exons where mutations are clustered (exons 16, 
30, 38 and 40) were studied first, followed by screening of exons 1, 10, 24, 25, 26, 31, 
32 and 37 and then of all the other exons. For WAS analysis, single strand 
conformation polymorphism (SSCP) was followed by sequencing of exons with mobility 
shifts, as described [10]. To screen for the c.515C>T Bolzano mutation in GP1BA, a 
fragment spanning the mutation was amplified and digested with HpaI, as described 
[11]. Sequence analysis of GP1BA was carried out in the family with the p.Ala172Val 
mutation to genotype two polymorphic intragenic loci, rs6065 and a variable number of 
tandem repeats (VNTR), for haplotype determination. For nomenclature, NCBI 
reference sequences NM_002473.3, NM_000173.5, NM_015175.2, NM_000377, and 
NM_014915.2 and D43968 were used for MYH9, GP1BA, NBEAL2, WAS, ANKRD26 
and RUNX1, respectively.  
 
Statistical analysis 
Comparison between continuous variables was performed using the student t test or 
the Mann-Whitney-Wilcoxon test, while correlation between MPV and MPD was 
assessed using the Spearman rank correlation coefficient. 
 
Results 
 
Patients 
Thirty-one patients belonging to 14 pedigrees were included, median age was 31 (2-
72), 17 patients were female. Fourteen patients had been misdiagnosed as ITP and 
treated with corticosteroids, danazol or IVIG, with no or transient partial response, while 
no patient had been splenectomized. Whereas in 9 (64%) pedigrees the transmission 
pattern was clearly autosomal dominant, in the other pedigrees we could not determine 
whether thrombocytopenia was transmitted as X-linked or autosomal recessive trait or 
as the result of a de novo event. In five pedigrees, there were clinical features 
suggestive of syndromic thrombocytopenias. In particular, 5 patients from pedigrees I 
and II had end-stage renal failure and/or hearing loss, patient from pedigree X had birth 
defects including mitral valve dysplasia, annular pancreas and psychomotor 
retardation, while 2 patients from pedigree XIII and one from pedigree XIV developed 
myeloid neoplasms. Bleeding was mild to moderate in most patients, except for 4 
patients who had severe bleeding. WHO bleeding score was grade 0, 1, 2, 3 and 4 in 
A
cc
ep
te
d 
A
rt
ic
le
 
© 2012 International Society on Thrombosis and Haemostasis 
3, 11, 9, 4 and 4 patients, respectively. Five patients died, two because of central 
nervous system bleeding after transformation to myeloid neoplasms, while 
subarachnoid hemorrhage during endovascular surgery, stroke and AML led to death 
in one patient each, respectively. Follow-up was 73 (1-259) months.  
 
Screening-phase studies 
Platelet count  
Platelet counts evaluated by microscopy were 77 (4-147) x109/L, while automated 
platelet counts were 63 (2-148) x109/L. In patients with macrothrombocytopenia lower 
automated compared to manual platelet counts were found, 32 (2-120) x109/L vs 65 
(12-145) x109/L, p<0.0001, reflecting underestimation of platelet counts by electronic 
counters. 
 
Platelet size and blood smear examination 
MPV was 9.05 (5.45-19) fL, while MPD was 3.24 (1.46-5.94) μm, reference values 6.2-
10.4 fL and 2.27-3.08 μm, respectively. MPV could not be determined in 4 patients with 
large platelets because of abnormalities in cell distribution histograms. Correlation was 
found between MPV and MPD, r=0.61, p=0.002, figure 1. However, discrepancy 
between the two parameters was found in patients from pedigree IX, who had normal 
MPV, while a population of large platelets was evident in the smear and MPD was 
increased. Overall, ten pedigrees (I to X) had large platelets, pedigree XI had small 
platelets and three pedigrees (XII to XIV) harboured normal-sized platelets. In patients 
with macrothrombocytopenia, MPV was 11.6 (8.4-19) fL and MPD was 3.91 (3.09-5.94) 
μm, which differed significantly from controls, p<0.0001 for both. Granulocyte 
inclusions reminiscent of Döhle bodies were present on smears from pedigrees II, III 
and IV, consistent with MYH9-RD. Besides, large platelets with a pale appearance 
were evident in pedigree IX. 
 
Platelet aggregation 
Platelet aggregation was evaluable in 18 patients, who had platelet counts above 100 
x109/L in PRP. Decreased aggregation responses to all agonists, including ADP, 
epinephrine, arachidonic acid and collagen, were found in 7 patients (pedigrees IV, IX, 
XII, XIII). Agglutination induced by 1.5mg/mL ristocetin was absent in the patient from 
pedigree V, who had absent response to von Willebrand factor (VWF)-containing 
bovine fibrinogen, pointing to Bernard-Soulier syndrome (BSS). In addition, SPA and 
enhanced RIPA were found in the patient from pedigree VII on repeated testing, 
suggesting platelet-type (PT-VWD) or type 2B von Willebrand disease (2BVWD).  
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Diagnostic suspicion raised during the screening phase 
First-step evaluation studies, which are summarized in table 1, raised the diagnostic 
suspicion of specific disorders in 9 of 14 pedigrees. In particular, diagnosis of MYH9-
RD, BSS, P-T/2B VWD, GPS, X-linked thrombocytopenia (XLT) and familial platelet 
disorder with predisposition to acute myeloid leukemia (FPD/AML) were considered in 
pedigrees I to IV, V, VII, IX, XI and XIII, respectively. 
 
Confirmatory tests 
Surface glycoprotein expression by flow cytometry 
Platelet glycoprotein expression was evaluated in 15 patients with 
macrothrombocytopenia, revealing high MFI for CD61, 181 (125-377) %, CD42a, 150 
(129-263) %, and CD42b, 137 (126-222) %, in 11, 7 and 8 patients, respectively, 
reflecting larger surface area. However, in 6 cases (pedigrees II, IV, VI, and VII), 
decreased CD42a and CD42b relative to CD61 values were found, 53.8 (41.1-69.2) % 
and 52.4 (21.6-69.7) % of control, respectively. In addition, markedly reduced GPIbα 
expression was shown for patient from pedigree V, who showed less than 1% CD42b-
positive platelets, MFI was 2% of control, while GPIX expression was moderately 
decreased, 64% of platelets stained positive for CD42a and MFI was 43% of control, 
consistent with BSS.  
 
Myosin-9 distribution pattern in granulocytes 
Myosin-9 aggregates were evident in granulocytes of patients from pedigrees I to IV. 
Immunofluorescence pattern in pedigrees I and II was characterized by numerous 
small (<0.5μm) aggregates, while one to four main large inclusions (2-5μm), round or 
oval, often together with further small aggregates were evident in pedigrees III and IV. 
MYH9-RD was excluded by the absence of myosin-9 aggregates in probands with 
large platelets and no definite diagnostic suspicion. 
 
Analysis of platelet thrombospondin-1 content 
A marked reduction in α-granule content was observed in pedigree IX, as 93% and 
96% of platelets from both patients displayed <5 TSP1-positive granules, respectively, 
whereas platelets from control individuals showed a packed granular pattern, with only 
4.4 (2-6.2)% of platelets harbouring <5 granules. A substantial, albeit more moderate, 
decrease in α-granule content was also found in the patient from pedigree X, in whom 
62.7% of platelets had <5 granules. Electron microscopy was available for this patient, 
confirming the reduction in α-granules (data not shown). Besides, a mild reduction in α-
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granule content, ranging from 12.5 to 14.5% of platelets <5 granules, was evident in 3 
patients from pedigree XII. 
 
Mutational screening of candidate genes 
MYH9 mutations were found in pedigrees I to IV, two of which were located in 
frequently affected hotspots, including c.2105G>A (p.Arg702His) (pedigree I) and 
c.4270G>A (p.Asp1424Asn) (pedigree III), while identification of the c.284C>A 
(p.Ala95Asp) mutation, in pedigree II has been recently reported [12]. In addition, a 
novel c.2539_2559dup (p.Met847_Glu853) in exon 20 was identified in pedigree IV (De 
Rocco et al, submitted). Of the four mutations, p.Asp1424Asn is a de novo event as it 
was not detected in the proband’s parents. In the patient from pedigree V, who had 
markedly reduced GPIbα, a novel homozygous c.882C>G mutation resulting in 
p.Tyr294* was detected in GP1BA, confirming BSS. Her parents and sister were 
heterozygous carriers for this mutation and two of them had platelet macrocytosis and 
moderately decreased GPIbα expression, 33% and 50% of control, respectively, while 
platelet count was at the lower limit of normal in one case. Besides, the Bolzano variant 
c.515C>T (p.Ala172Val) in GP1BA was found in patients from pedigree VI, who had 
reduced GPIb/IX relative to GPIIIa expression, and monoallelic BSS was diagnosed. 
The three patients belonging to this pedigree were all carriers of at least one T allele of 
SNP rs6065 and B variant of the VNTR, suggesting that they share the same haplotype 
as that identified in other patients with the same mutation [11].  On the other hand, 
screening of GP1BA and of the region of VWF exon 28 encoding residues 1266-1461, 
where mutations are usually identified in type 2B VWD, disclosed no abnormality in the 
patient from pedigree VII, who had SPA and enhanced RIPA. In patients from pedigree 
IX, who were characterized by markedly reduced α-granules, a novel homozygous 
c.2187C>A mutation yielding p.Tyr729* in NBEAL2 was identified, confirming diagnosis 
of GPS (Bottega et al, submitted). Clinical and molecular features of this pedigree are 
shown in Figure 2. On the other hand, no NBEAL2 mutation was identified in patient 
from pedigree X, even if she had substantial although not complete α-granule 
reduction. X-linked thrombocytopenia was diagnosed in the only pedigree with non-
syndromic thrombocytopenia harbouring small platelets (pedigree XI), based on the 
finding of c.156G>C (p.Gln52His) mutation in exon 2 of WAS, where the majority of 
mutations causing XLT are located. Regarding patients with normal-sized platelets, 
identification of c.653delC (p.Thr219Argfs*8) C-terminal RUNX1 mutation in pedigree 
XIII has been previously described [13], while no mutation in RUNX1 was found in 
pedigree XIV. Patients with thrombocytopenia and normal-sized platelets of unknown 
molecular etiology (pedigrees XII and XIV) were screened for ANKRD26 mutations and 
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the c.-127A>G substitution in 5´-UTR of ANKDR26 was detected in pedigree XII, where 
mutations causing THC2 have been reported to be clustered.  Family tree for this 
pedigree is shown in Figure 3. Results of confirmatory tests are summarized in Table 2. 
 
Discussion 
 
Recent progress in the field of inherited platelet disorders has contributed to better 
understanding of these genetic conditions, leading to improved approach to patient 
diagnosis and care. Accurate diagnosis of IT may be challenging due to the relative 
rarity of these heterogeneous conditions, as well as atypical presentation of known 
disorders and the need to identify new genetic defects in patients who do not fit into 
established categories. Adoption of established algorithms may be useful to optimize 
diagnostic strategies. In this regard, application of the algorithm proposed by the italian 
group led to diagnosis in 22 of 46 unrelated patients studied in Italy [15]. However, 
even when diagnostic guidelines have been established, the required diagnostic 
technologies are not always readily available and referral to specialized centers may be 
necessary for definitive diagnosis. To maximize utilization of local, low-cost resources, 
we applied the aforementioned algorithm to patients with IT in a single center in 
Argentina, which proved useful as an initial approach to diagnosis and helped guide 
further, more complex studies, some of which were performed at a referral center with 
known expertise in this field. This approach led to a definitive diagnosis in 10 (71.4%) 
of 14 pedigrees included in this study. This figure compares favorably with those 
reported in the literature, in which only around half of the patients with IT were given a 
definitive diagnosis [15]. Feasibility of this strategy was based on the development of a 
collaboration program between centers in Argentina and Italy and its success was 
facilitated by sustained commitment of both partner sites. Extension of this project to 
other regional centers would be useful to assess whether this high diagnostic yield is 
maintained. This initiative may serve as a model for developing international networks 
in which centers from developing or middle-income countries team up with referral 
centers from resourceful nations.  
As described in other cohorts, the majority of patients included in this series harbored 
large platelets and MYH9-RD comprised the most frequent single disorder. Consistent 
with findings raised by a genotype-phenotype study [16], patients with mutations at 
position 702 (pedigree I) had severe disease with early-onset extrahematological 
involvement, while patients carrying tail domain mutations (pedigrees III and IV) 
presented with a milder phenotype characterized by isolated moderate 
thrombocytopenia.  Besides, patients harboring the p.Ala95Asn mutation (pedigree II) 
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had severe thrombocytopenia and early-onset hearing loss but no renal disease, 
highlighting that the risk of renal impairment in patients with motor domain mutations 
located at positions other than 702 is not clear [12]. The pattern of myosin-9 distribution 
differed between patients with motor domain respect to those with tail domain 
mutations, as the former displayed a speckled pattern while the latter showed large 
aggregates. This observation is in agreement with a recent study, in which 
immunofluorescence pattern was proposed as a useful clue to guide the choice of 
candidate exons for optimized mutational screening [8]. Besides, the finding of low 
GPIb-IX relative to GPIIIa expression in two of four MYH9-RD pedigrees in this cohort 
has been previously observed in other MYH9-RD patients [17]. 
Macrothrombocytopenias involving abnormalities in GPIbα were identified in two 
additional pedigrees. Markedly decreased GPIbα levels were found in a patient with 
classical BSS, in whom a novel GP1BA homozygous mutation was found. Besides, the 
finding of decreased GPIb-IX relative to GPIIIa expression in another pedigree led us to 
consider the diagnosis of monoallelic form of BSS, which was confirmed by the 
identification of a heterozygous Bolzano mutation. Monoallelic dominant BSS due to 
the Bolzano variant represents a frequent cause of macrothrombocytopenia in Italy and 
a founder effect for this mutation has been described in Southern Italy [11]. However, it 
is unknown whether this mutation occurs outside this country. The fact that patients 
from the Argentinian pedigree are likely to share the same haplotype as that described 
in Italian patients suggests a common origin for this mutation, and may reflect 
immigration of the Italian population to Argentina. Finally, SPA and enhanced RIPA, 
suggesting increased affinity between VWF and GP1bα, was a prominent feature in 
another patient in this cohort, although inconclusive results of mixing assays did not 
allow us to determine the origin of this abnormality (data not shown). No mutation was 
identified in GP1BA and in the mutational hot spot region of VWF exon 28. Failure to 
identify mutations in both VWF exon 28 and GP1BA in patients with phenotypic 
features of P-T/2B VWD has been recently highlighted, suggesting involvement of 
other genes or alternative diagnosis [18].  
The finding of markedly decreased platelet TSP1-positive granules in another pedigree, 
strengthened by the detection of myelofibrosis, splenomegaly and high B12 levels, led 
to diagnostic suspicion of GPS, which was confirmed by the identification of a novel 
homozygous NBEAL2 mutation, illustrating the usefulness of assessing TSP1 content 
by immunofluorescence as a marker for α-granules, as shown previously [9]. In 
addition, a mild reduction in α-granules was found in patients with THC2, as reported 
for other pedigrees [19], indicating that, although not present in all patients, this finding 
may suggest the presence of ANKRD26 mutations in patients with normal-sized 
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platelets. Staining for TSP1 could thus be included among the second-phase 
evaluation studies proposed in the algorithm, especially if electron microscopy is 
unavailable. On the other hand, no NBEAL2 mutation was found in the patient with 
large platelets and birth defects, who had substantial α-granule reduction. Among 
macrothrombocytopenias associated with congenital malformations, Jacobsen 
syndrome was excluded because of absence of typical giant α-granules, normal 
karyotype and normal MPLA for subtelomeric regions, which ruled out 11q terminal 
deletion, while 22q11.2 microdeletion syndrome was deemed unlikely because of 
normal GPIb expression, although more specific molecular studies could not be 
performed to definitively exclude this possibility. More sophisticated genetic 
technologies, such as next generation sequencing, SNP genotyping arrays and array-
comparative genomic hybridization (CGH), may help identify new disease loci in 
patients with unrecognized forms of thrombocytopenia associated with congenital 
malformations.  
Regarding disorders with normal-sized platelets, the recent identification of ANKRD26 
mutations in THC2 has contributed to diagnosis in this subset of patients, and, to date, 
21 such pedigrees have been reported [2,19]. Although the pathogenic effects of these 
mutations are currently under investigation, they may lead to increased ANKRD26 
expression which may interfere with megakaryocyte maturation and platelet production. 
In our cohort, c.-127A>G substitution in ANKRD26 was found in a pedigree with clinical 
features resembling those of previously described patients [19]. Affected individuals 
have non-syndromic autosomal dominant mild to moderate thrombocytopenia with few 
bleeding manifestations and normal or mildly decreased platelet aggregation. Of 
interest considering the increased frequency of leukemia found in some THC2 
pedigrees [19], a relative of affected individuals died of acute leukemia, highlightening 
the need for further studies to define the risk of leukemia in this disorder. With regards 
to other patients characterized by normal-sized platelets, the presence of severe 
platelet dysfunction, development of myeloid neoplasms and the finding of a RUNX1 
mutation led to diagnosis of FPD/AML in another pedigree [13], while no mutations in 
ANKRD26 or RUNX1 were found in the remaining one and molecular diagnosis 
remained undetermined in this family, in which one affected member had developed a 
myeloid neoplasm. Of note, platelet dysfunction, which seems to be a constant feature 
of FPD/AML, was absent in this pedigree. Microdeletions involving RUNX1, which may 
have been missed by sequencing, have been reported to cause thrombocytopenia and 
leukemia predisposition although, unlike these patients, most affected individuals 
display dysmorphic features or mental retardation. Array-CGH may be useful in this 
setting [20].  
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In conclusion, given the rarity of IT, increased awareness of these conditions, adoption 
of established diagnostic algorithms and collaborative international efforts should 
facilitate advances in patient diagnosis and care, as well as help identify new genetic 
defects in patients who do not fall into known categories. In addition, despite 
identification of the causative genetic defect, the intrinsic mechanisms underlying 
thrombocytopenia in some of these disorders are still incompletely understood and 
collaborative research may enable the homogeneous study of larger patient cohorts, 
providing unique opportunities to gain further insight into the molecular regulation of 
platelet production and function.  
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Table 1. Patient features and results of screening studies 
 
Age, Platelet count, WHO bleeding score Syndromic Platelet size Blood smear Platelet aggregation
years (range) (x109/L) (range) [No. of patients]
I [2] 25 (10-40) 34.5 (34-35) 3 [1], 4 [1] HL, CRF large --- normal
II [3] 31 (27-70) 20 (12-22) 1 [2], 2 [1] HL large Döhle-like inclusions NE
III [1] 19 42 1 no large Döhle-like inclusions reduced response to  ADP
IV [2] 17.5 (2-33) 86 (76-96) 0 [1], 2 [1] no large Döhle-like inclusions mildly decreased
V [1] 4 110 4 no large --- absent RIPA
VI [3] 34 (24-53) 102 (86-130) 1 [3] no large --- normal
VII [1] 40 145 2 no large --- SPA, enhanced RIPA
VIII [1] 25 42 0 no large --- normal
IX [2] 56 (53-59) 47.5 (30-65) 2 [2] no large pale platelets mildly decreased
X [1] 11 65 3 CM large --- NE
XI [2] 9.5 (5-14) 25 (15-35) 2 [2] no small --- NE
XII [4] 50 (14-72) 85 (68-147) 0 [1], 1 [3] no normal --- normal/mildly decreased
XIII [5] 32 (9-53) 82 (10-145) 2 [2], 3 [2], 4 [1] CMML, AML normal --- decreased
XIV [3] 32 (26-55) 86 (4-105) 1 [2], 4 MDS/MPN normal --- normal
First diagnostic phasePedigree
[No.of
patients]
Patient features
 
WHO, World Health Organization; HL, hearing loss; CRF, chronic renal failure; CM, 
congenital malformations; CMML, chronic myelomonocytic leukemia; AML, acute 
myeloid leukemia; MDS/MPN, mixed myelodysplastic myeloproliferative syndrome; ---, 
indicates no relevant abnormalities besides abnormal platelet size; NE, non-evaluable; 
SPA, spontaneous platelet aggregation; RIPA, ristocetin-induced platelet aggregation. 
Bleeding was assessed according to WHO bleeding scale: grade 0 indicates no 
bleeding; 1. petechiae; 2, 3 and 4, mild, gross and debilitating blood loss, respectively. 
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Table 2. Results of specialized studies and final diagnosis in IT patients 
Pedigree Diagnosis Ref
Flow cytometry Immunofluorescence† Molecular studies
I normal myosin-9 aggregates p.Arg702His MYH9  mutation  MYH9-related disease 14
II low GPIb/GPIIIa ratio myosin-9 aggregates p.Ala95Asn MYH9 mutation MYH9-related disease 12
III normal myosin-9 aggregates p.Asp1424Asn MYH9 mutation MYH9-related disease -
IV low GPIb/GPIIIa ratio myosin-9 aggregates p.Met847_Glu853 MYH9  mutation MYH9-related disease ¶
V markedly reduced GPIbα   - p.Tyr294* GP1BA mutation‡ Bernard-Soulier syndorme -
VI low GPIb/GPIIIa ratio   - p.Ala172Val GP1BA mutation Monoallelic Bernard-Soulier -
VII low GPIb/GPIIIa ratio   - no mutation in GP1BA  and VWF  exon 28 UD -
VIII normal   - ND UD -
IX normal markedly reduced TSP1 p.Tyr729* NBEAL2 mutation Gray platelet syndrome **
X normal moderately reduced TSP1 no mutation found in NBEAL2 UD -
XI normal   - p.Gln52His WAS mutation X-linked thrombocytopenia 10
XII normal mildly reduced TSP1 c.-127A>G ANKRD26  mutation Thrombocytopenia 2 -
XIII normal   - p.Thr219Argfs*8 RUNX1 mutation§ FPD/AML 13
XIV normal   - normal RUNX1  & ANKRD26 UD -
Second-phase studies
 
†only positive findings are indicated; ‡amino acid position of precursor glycoprotein; §the 
p.Thr219Argfs*8 mutation, described according to current nomenclature 
recommendations (www.hgvs.org/mutnomen), was previously reported as 
Pro218fsTer22513, ¶De Rocco et al et al, submitted, **Bottega et al, submitted.  
ND, indicates not done; UD, undefined; FPD/AML, familial platelet disorder with 
predisposition to acute myelogenous leukemia; Ref, reference.  
Novel mutations are shown in bold. 
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Legends to figures 
Figure 1. Correlation between mean platelet volume (MPV) and mean platelet 
diameter (MPD) in patients with inherited thrombocytopenia.  MPV was assessed 
by using an automated cell counter, while MPD was determined on blood smears by 
measuring the largest platelet diameter with an image analysis software. Dotted lines 
represent reference values for MPV and MPD. Filled symbols represent patients in 
whom MPV and MPD values agree while empty symbols show patients from pedigree 
IX, in whom discrepant results were found between the two parameters, as MPV was 
normal while MPD was increased.  
Figure 2. Features of a pedigree with gray platelet syndrome. (A). Family pedigree. 
Thrombocytopenia was detected in two brothers (II.1 and II.2) at age 53 and 42 born to 
consanguineous parents. Squares indicate males; circles, females; black symbols, 
thrombocytopenia; open symbols, normal platelet counts and question mark, unknown 
platelet status. A c.2187C>A homozygous mutation in NBEAL2 was identified in 
patients II.1 and II.2, while III.1, III.2 and III.3, as expected, were heterozygous carriers 
for this mutation. (B). Sequencing data. Chromatogram showing the presence of an 
homozygous c.2187C>A mutation yielding p.Tyr729* in NBEAL2. (C). 
Immunofluorescence analysis for thrombospondin-1. Staining for TSP1 was performed 
by incubation with an anti-TSP1 antibody followed by a FITC-conjugated secondary 
antibody (green) and platelets were identified by F-actin staining with TRITC-
conjugated Phalloidin (red) and examined under a fluorescence microscope (BX51, 
Olympus) (x100). Compared to control (top panel), platelets from patient II.2 (lower 
panel) show decreased numbers of TSP1-positive granules. (D). Gomori´s silver 
staining for reticulin fibers in the bone marrow. Diffuse and dense fiber network with 
intersections (grade 2 according to the European Consensus grading system) is shown 
for patient II.2 by light microscopy (x40).  
Figure 3. Features of a pedigree with Thrombocytopenia 2 (THC2). (A). Family 
pedigree XII. The founder pedigree and partial pedigrees of 3 members of generation II 
are shown. Squares represent males; circles, females; black symbols indicate  
thrombocytopenia associated with the presence of heterozygous ANKRD26 mutation; 
dark gray symbols, documented thrombocytopenia; pale gray, reported 
thrombocytopenia; open symbols, normal platelet counts; question mark, unknown 
platelet status and the striped symbol (II.1) represents an individual who developed 
acute leukemia. (B). Mutational screening revealed the presence of a heterozygous c.-
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127A>G (*) in 5’-UTR of ANKRD26 in II.3, III.3, IV.6 and IV.7, while it was absent in 
III.2. Mutational screening was not carried out in the other thrombocytopenic patients. 
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